Trial Profile
Efficacy and Safety Phase Ib Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Albumin-granulocyte colony-stimulating factor fusion protein Beijing BioFortune/Tianjin SinoBiotech (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Tianjin SinoBiotech
- 15 Aug 2017 New trial record